CRISPR THERAPEUTICS AG Net Income (Loss) Attributable to Noncontrolling Interest
CRISPR THERAPEUTICS AG (CRSP) reported Net Income (Loss) Attributable to Noncontrolling Interest of -$25.00 thousand for the 12-month period ending 2016-12-31, per its 10-K filed 2019-02-25.
Discontinued › Income Statement › Net Income
us-gaap:NetIncomeLossAttributableToNoncontrollingInterest · last filed 2019-02-25
- CRISPR THERAPEUTICS AG net income (loss) attributable to noncontrolling interest for the quarter ending 2016-12-31 was -$1.00K.
- CRISPR THERAPEUTICS AG net income (loss) attributable to noncontrolling interest for the quarter ending 2016-09-30 was -$14.00K.
- CRISPR THERAPEUTICS AG net income (loss) attributable to noncontrolling interest for the quarter ending 2016-06-30 was -$7.00K.
- CRISPR THERAPEUTICS AG net income (loss) attributable to noncontrolling interest for the quarter ending 2016-03-31 was -$3.00K.
- CRISPR THERAPEUTICS AG net income (loss) attributable to noncontrolling interest for fiscal 2016 was -$25.00K.
- CRISPR THERAPEUTICS AG net income (loss) attributable to noncontrolling interest for fiscal 2015 was -$325.00K.
- CRISPR THERAPEUTICS AG net income (loss) attributable to noncontrolling interest for fiscal 2014 was -$536.00K.
| Period end | Net Income (Loss) Attributable to Noncontrolling Interest 3 month | Net Income (Loss) Attributable to Noncontrolling Interest 6 month | Net Income (Loss) Attributable to Noncontrolling Interest 9 month | Net Income (Loss) Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2016-12-31 | -$1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-25 | -$15.00K derived: sum of 2 quarters · filed 2019-02-25 | -$22.00K derived: sum of 3 quarters · filed 2019-02-25 | -$25.00K 10-K · filed 2019-02-25 |
| 2016-09-30 | -$14.00K 10-Q · filed 2017-11-08 | -$21.00K derived: sum of 2 quarters · filed 2017-11-08 | -$24.00K 10-Q · filed 2017-11-08 | -$40.00K derived: sum of 4 quarters · filed 2018-03-08 |
| 2016-06-30 | -$7.00K 10-Q · filed 2017-08-10 | -$10.00K 10-Q · filed 2017-08-10 | -$26.00K derived: sum of 3 quarters · filed 2018-03-08 | -$27.00K derived: sum of 4 quarters · filed 2018-03-08 |
| 2016-03-31 | -$3.00K 10-Q · filed 2017-05-11 | -$19.00K derived: sum of 2 quarters · filed 2018-03-08 | -$20.00K derived: sum of 3 quarters · filed 2018-03-08 | |
| 2015-12-31 | -$16.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08 | -$17.00K derived: sum of 2 quarters · filed 2018-03-08 | -$325.00K 10-K · filed 2018-03-08 | |
| 2015-09-30 | -$1.00K 10-Q · filed 2016-11-22 | -$309.00K 10-Q · filed 2016-11-22 | ||
| 2014-12-31 | -$536.00K 10-K · filed 2017-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |